Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

• Hoofdauteurs: Max Robles-Nasta (Auteur), Daniela Sánchez-Bonilla (Auteur), Moises M. Gallardo-Pérez (Auteur), Edgar J. Hernández-Flores (Auteur), Merittzel A. Montes-Robles (Auteur), María de L. Pastelín-Martínez (Auteur), Juan C. Olivares-Gazca (Auteur), Guillermo J. Ruiz-Delgado (Auteur), Guillermo J. Ruiz-Argüelles (Auteur)
• Formaat: Boek
• Gepubliceerd in: Permanyer, 2024-04-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias. Tyrosine-kinase inhibitors are considered front-line therapy in high-income countries, whereas allogeneic hemato...